Regeneron Pharmaceuticals, Inc. (REGN) has a consensus analyst rating of Buy, based on 48 analysts covering the stock. Of those, 34 recommend buying, 14 recommend holding, and 0 recommend selling.
The analyst consensus price target for REGN is $862.74, representing a +14.2% upside from the current price of $755.51. Price targets range from a low of $700.00 to a high of $1,057.00.
